References in periodicals archive ?
(NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that it has been awarded a new $670,621Small Business Innovation Research(SBIR) grant to advance its Vision Restoration Program, the Company's proprietary and innovative program generating 3-dimensional human retinal tissue derived from pluripotent cells.
Release date- 12082019 - Lineage Cell Therapeutics, Inc.(NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced the effective change of its corporate name and formal launch of its new corporate brand.
In conjunction with the name change, the Company's ticker symbol will change to 'LCTX' on August 12, 2019.
In connection with the launch, the Company's NYSE American ticker symbol will change to 'LCTX' and will be effective at the open of the market on August 12, 2019.
Acronyms browser ?
Full browser ?